Peer-Reviewed Publications

CPCE investigators are international experts in their clinical effectiveness-related fields, and have authored hundreds of pediatric research articles in leading peer-reviewed journals. From here you can access CPCE journal article abstracts by author, title, or year.

Found 43 results
Author [ Title(Desc)] Year
Filters: Author is Alonzo, Todd A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Lamble AJ, Brodersen LEidenschin, Alonzo TA, et al. "CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group." J Clin Oncol. 2021:JCO2101595.
Pollard JA, Loken MR, Gerbing RB, et al. "CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531." J. Clin. Oncol.. 2016;34(7):747-55.
Lamba JK, Chauhan L, Shin M, et al. "CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531." J. Clin. Oncol.. 2017:JCO2016712513.
Miller TP, Li Y, Kavcic M, et al. "Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: A report from the Children's Oncology Group." Haematologica. 2017.
Johnston DL, Alonzo TA, Gerbing RB, et al. "Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2017.
Hoff FW, van Dijk AD, Qiu Y, et al. "Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study." Haematologica. 2022.
Vujkovic M, Aplenc R, Alonzo TA, Gamis AS, Li Y. "Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group." Front Genet. 2016;7:139.
Miller TP, Troxel AB, Li Y, et al. "Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2015;62(7):1184-9.
Miller TP, Getz KD, Kavcic M, et al. "A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group." Leuk. Lymphoma. 2016:1-8.
Getz KD, Li Y, Alonzo TA, et al. "Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2015;62(10):1775-81.
Smith JL, Ries RE, Hylkema T, et al. "Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options - A COG and TARGET Pediatric AML Study." Clin. Cancer Res.. 2019.
Vujkovic M, Attiyeh EF, Ries RE, et al. "Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group." Cancer Genet. 2015;208(7-8):408-13.
Getz KD, Alonzo TA, Sung L, et al. "Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2021:e29313.

Pages